Overview Dividends

(GSK) GlaxoSmithKline - Ratings and Ratios

Exchange: NYSE • Country: United Kingdom • Currency: USD • Type: Common Stock • ISIN: US37733W2044

Vaccines, Specialty Medicines, Oncology, Respiratory, General Medicines

EPS (Earnings per Share)

EPS Growth (3y CAGR): 37.22%
EPS Trend (3y Corr): 48.5%

Last SUE: 4.00σ
Qual. Beats: 7

Revenue

Revenue Growth (3y CAGR): 272.10%
Revenue Trend (3y Corr): 50.5%

Last SUE: 4.00σ
Qual. Beats: 1

Risk via 10d forecast
Volatility	24.3%
Value at Risk 5%th	37.5%
Relative Tail Risk	-5.93%

Reward TTM
Sharpe Ratio	1.33
Alpha	36.63

Character TTM
Hurst Exponent	0.407
Beta	0.229
Beta Downside	0.233

Drawdowns 3y
Max DD	28.46%
Mean DD	8.91%
Median DD	7.57%

Description: GSK GlaxoSmithKline September 26, 2025

GSK plc (NYSE:GSK) develops, manufactures, and markets vaccines, specialty medicines, and general medicines across the United Kingdom, United States, and global markets, operating through Commercial Operations and Total R&D segments.

Its specialty portfolio targets oncology (e.g., ovarian and endometrial cancers), respiratory-immunology (e.g., eosinophil-driven asthma), inflammation, and HIV-related inhaled therapies, while its vaccine suite spans shingles, RSV, seasonal influenza, HPV, and a broad range of pediatric and adult immunizations.

In 2023, GSK reported revenue of ≈ £34 billion, with a dividend yield of ≈ 5.3% and a free cash flow conversion of ≈ 70%, underscoring its cash-generating capacity despite ongoing pricing pressure in mature markets.

Key sector drivers include an aging global population that expands demand for chronic-disease treatments, heightened public-health focus on vaccine preparedness post-COVID-19, and regulatory trends toward price-cap mechanisms in Europe that compress margins for generic-competitor products.

GSK’s strategic collaboration with CureVac to develop mRNA vaccines for infectious diseases reflects a pivot toward next-generation platform technologies, a move that could diversify its pipeline and mitigate reliance on traditional protein-based vaccines.

For a deeper quantitative assessment of GSK’s valuation metrics, you may find the ValueRay platform useful.

GSK Stock Overview

Market Cap in USD	95,493m
Sub-Industry	Pharmaceuticals
IPO / Inception	1986-07-09
Return 12m vs S&P 500	28.4%
Analyst Rating	2.88 of 5

GSK Dividends

Metric	Value
Dividend Yield	3.51%
Yield on Cost 5y	5.60%
Yield CAGR 5y	-6.74%
Payout Consistency	90.7%
Payout Ratio	37.4%

GSK Growth Ratios

Metric	Value
CAGR 3y	17.21%
CAGR/Max DD Calmar Ratio	0.60
CAGR/Mean DD Pain Ratio	1.93
Current Volume	3735k
Average Volume	5027.4k

Piotroski VR‑10 (Strict, 0-10) 4.5

Net Income (15.09b TTM) > 0 and > 6% of Revenue (6% = 17.83b TTM)

FCFTA 0.36 (>2.0%) and ΔFCFTA 29.04pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 2.04% (prev -13.29%; Δ 15.32pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.47 (>3.0%) and CFO 6.09b <= Net Income 15.09b (YES >=105%, WARN >=100%)

Net Debt (-5.57b) to EBITDA (25.43b) ratio: -0.22 <= 3.0 (WARN <= 3.5)

Current Ratio 3.34 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (2.05b) change vs 12m ago 0.54% (target <= -2.0% for YES)

Gross Margin 37.69% (prev 71.55%; Δ -33.86pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 838.2% (prev 53.94%; Δ 784.2pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 35.98 (EBITDA TTM 25.43b / Interest Expense TTM 640.0m) >= 6 (WARN >= 3)

Altman Z'' 13.49

(A) 0.47 = (Total Current Assets 8.64b - Total Current Liabilities 2.59b) / Total Assets 12.88b

(B) 0.78 = Retained Earnings (Balance) 10.02b / Total Assets 12.88b

(D) 3.34 = Book Value of Equity 10.02b / Total Liabilities 3.00b

Total Rating: 13.49 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 79.61

1. Piotroski 4.50pt = -0.50

2. FCF Yield 7.01% = 3.50

3. FCF Margin 1.58% = 0.40

4. Debt/Equity 0.03 = 2.50

5. Debt/Ebitda -0.22 = 2.50

6. ROIC - WACC (= 73.37)% = 12.50

7. RoE 102.7% = 2.50

8. Rev. Trend 50.47% = 3.79

9. EPS Trend 48.54% = 2.43

What is the price of GSK shares?

As of November 18, 2025, the stock is trading at USD 47.53 with a total of 3,734,979 shares traded.
Over the past week, the price has changed by +1.24%, over one month by +9.19%, over three months by +22.72% and over the past year by +47.14%.

Is GSK a buy, sell or hold?

GlaxoSmithKline has received a consensus analysts rating of 2.88. Therefor, it is recommend to hold GSK.

Strong Buy: 1
Buy: 0
Hold: 5
Sell: 1
Strong Sell: 1

What are the forecasts/targets for the GSK price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	47.6	0.2%
Analysts Target Price	47.6	0.2%
ValueRay Target Price	56.5	18.9%

GSK Fundamental Data Overview November 17, 2025

Market Cap GBP = 72.57b (95.49b USD * 0.76 USD.GBP)
P/E Trailing = 13.48
P/E Forward = 9.3197
P/S = 2.9688
P/B = 4.4714
P/EG = 0.4141
Beta = 0.231
Revenue TTM = 297.24b GBP
EBIT TTM = 23.03b GBP
EBITDA TTM = 25.43b GBP
Long Term Debt = 13.70b GBP (from longTermDebt, last fiscal year)
Short Term Debt = 242.0m GBP (from shortTermDebt, last quarter)
Debt = 478.0m GBP (from shortLongTermDebtTotal, last quarter)
Net Debt = -5.57b GBP (from netDebt column, last quarter)
Enterprise Value = 67.01b GBP (72.57b + Debt 478.0m - CCE 6.04b)
Interest Coverage Ratio = 35.98 (Ebit TTM 23.03b / Interest Expense TTM 640.0m)
FCF Yield = 7.01% (FCF TTM 4.70b / Enterprise Value 67.01b)
FCF Margin = 1.58% (FCF TTM 4.70b / Revenue TTM 297.24b)
Net Margin = 5.08% (Net Income TTM 15.09b / Revenue TTM 297.24b)
Gross Margin = 37.69% ((Revenue TTM 297.24b - Cost of Revenue TTM 185.21b) / Revenue TTM)
Gross Margin QoQ = 34.75% (prev 72.89%)
Tobins Q-Ratio = 5.20 (Enterprise Value 67.01b / Total Assets 12.88b)
Interest Expense / Debt = 31.38% (Interest Expense 150.0m / Debt 478.0m)
Taxrate = 34.90% (6.22b / 17.83b)
NOPAT = 14.99b (EBIT 23.03b * (1 - 34.90%))
Current Ratio = 3.34 (Total Current Assets 8.64b / Total Current Liabilities 2.59b)
Debt / Equity = 0.03 (Debt 478.0m / totalStockholderEquity, last quarter 16.15b)
Debt / EBITDA = -0.22 (Net Debt -5.57b / EBITDA 25.43b)
Debt / FCF = -1.18 (Net Debt -5.57b / FCF TTM 4.70b)
Total Stockholder Equity = 14.69b (last 4 quarters mean from totalStockholderEquity)
RoA = 117.2% (Net Income 15.09b / Total Assets 12.88b)
RoE = 102.7% (Net Income TTM 15.09b / Total Stockholder Equity 14.69b)
RoCE = 81.10% (EBIT 23.03b / Capital Employed (Equity 14.69b + L.T.Debt 13.70b))
RoIC = 80.32% (NOPAT 14.99b / Invested Capital 18.66b)
WACC = 6.95% (E(72.57b)/V(73.05b) * Re(6.86%) + D(478.0m)/V(73.05b) * Rd(31.38%) * (1-Tc(0.35)))
Discount Rate = 6.86% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -33.33 | Cagr: -0.19%
[DCF Debug] Terminal Value 77.05% ; FCFE base≈4.54b ; Y1≈4.19b ; Y5≈3.79b
Fair Price DCF = 33.87 (DCF Value 68.05b / Shares Outstanding 2.01b; 5y FCF grow -9.75% → 3.0% )
EPS Correlation: 48.54 | EPS CAGR: 37.22% | SUE: 4.0 | # QB: 7
Revenue Correlation: 50.47 | Revenue CAGR: 272.1% | SUE: 4.0 | # QB: 1

Additional Sources for GSK Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle